Drugs / ETVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02531802 | Oct 2015 → Jul 2017 | diarrheal disease | PATH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-02-20 | Scandinavian Biopharma AB | Results Scandinavian Biopharma Announces Publication of ETVAX® Phase 2b Data in The Lancet Infectious Diseases and Confirms Phase 3 Readiness scandinavianbiopharma.se ↗
The trial confirmed an excellent safety profile and robust systemic immune responses against key ETEC antigens. |
| 2024-10-02 | Scandinavian Biopharma AB | Results Scandinavian Biopharma Announces Successful Completion of Pediatric Phase IIb Trial for ETVAX® Vaccine in The Gambia scandinavianbiopharma.se ↗
The protective efficacy was more than 80% against ETEC when allowing for any co-infections except parasites. |
| 2022-12-05 | Scandinavian Biopharma AB | Results New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines scandinavianbiopharma.se ↗
Dr. Nsofwa Sukwa, from the Centre for Infectious Disease Research in Zambia, presented results from our completed phase 1 age-descending study in Zambia where ETVAX ® was shown safe, tolerable, and immunogenic in Zambian adults and children. |
| 2021-09-28 | Scandinavian Biopharma AB | Results New ETVAX® data will be presented during VASE, a conference designed to spark innovation and accelerate the momentum for research and development on enteric vaccines scandinavianbiopharma.se ↗
Dr. Nsofwa Sukwa, from the Centre for Infectious Disease Research in Zambia, will present results from our recently completed phase 1 age descending study in Zambia where ETVAX ® was shown safe, tolerable, and immunogenic in Zambian adults and children. |
| 2020-11-05 | Scandinavian Biopharma AB | Results The World Health Organization concludes that ETEC remains a priority pathogen and is encouraged by our preliminary phase 2B results from Benin scandinavianbiopharma.se ↗
The Committee’s conclusion was that “The data from the ETVAX phase 2b study are encouraging, albeit preliminary”. |
| 2020-05-26 | Scandinavian Biopharma AB | Results Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa scandinavianbiopharma.se ↗
The study results confirm the excellent safety and overall positive immunogenicity of ETVAX®, as well as a significant protective efficacy of 56% against all severe diarrhea, independent of pathogen. |
| 2019-11-20 | Scandinavian Biopharma AB | Results Scandinavian Biopharma reports successful results of the oral, inactivated ETEC vaccine candidate ETVAX® against enterotoxigenic E. coli diarrhoea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh scandinavianbiopharma.se ↗
The successful results of the Phase I/II study in Dhaka, Bangladesh, are now published in The Lancet Infectious Diseases. |
| 2019-10-16 | Scandinavian Biopharma AB | Results The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland scandinavianbiopharma.se ↗
The study confirmed the safety and strong immunogenicity of ETVAX® and was conducted as a collaborative effort between University of Gothenburg (UG), icddr,b, and the international non-profit global health organisation PATH. |
| 2019-04-30 | Scandinavian Biopharma AB | Results Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin scandinavianbiopharma.se ↗
Primary results show that the incidence of TD is very high; ETEC is the most common pathogen; the vaccine has been safe and well tolerated and the vaccine coverage is as high as almost 90%. |
| 2013-05-21 | Scandinavian Biopharma AB | Results Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries scandinavianbiopharma.se ↗
A clinical Phase I study of a novel vaccine against diarrhea caused by ETEC has been successfully completed. |
| 2012-08-24 | Scandinavian Biopharma AB | Results Pressrelease – Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine scandinavianbiopharma.se ↗
The primary objectives of the study were met. |
All press releases naming this drug 23 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02531802 ↗ |
| Modality | Vaccine | “This trial tested an oral, inactivated, enterotoxigenic E coli vaccine (ETVAX)” PMID 31757774 ↗ Nov 2019 |
| Route | Oral | “administered orally on Day 0 and 14” NCT02531802 ↗ |